Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Australian Biotech Invest 2017
15 slides from Oncosil Medical's conference presentation, Oct 24, 2017
Slide 1: Advancing Pancreatic & Liver Cancer Treatment
For personal use only ASX.OSL Advancing Pancreatic & Liver Cancer Treatment Australian Biotech Invest 2017 October 24th Melbourne OncoSil Medical 1
Slide 2: Important notice
Important notice For personal use only This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide an overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presenta
Slide 3: Investment Highlights
Investment Highlights For personal use only • Developing a breakthrough implantable radiation treatment for Pancreatic and Liver cancer • Current and previous clinical studies demonstrate significant reduction in tumour size & volume, good safety and tolerability profile and ease of implantation • U
Slide 4: OncoSil Medical
OncoSil Medical OncoSilTM is a first in class medical device for the treatment of unresectable locally For personal use only advanced pancreatic cancer First in class technology Financial information Proprietary brachytherapy device that emits cancer-killing radiation into a Share price (as at 16-
Slide 5: OncoSil device overview
OncoSilTM device overview An implantable radiotherapy medical device targeting pancreatic and liver cancers For personal use only OncoSilTM is a single-use brachytherapy device Delivered through microparticles: 30-micron silicon particles contain beta-emitting Phosphorous32 (P32) OncoSilTM micropart
Slide 6: OncoSil procedure
OncoSilTM procedure The procedure is minimally invasive and allows for targeted radiation For personal use only Pancreas Liver OncoSil™ injected OncoSilTM dose is directly into the suspended in a tumour Endoscope Using CT or real-time specially formulated guided into the fluid for implantation imagi
Slide 7: EANM Congress – Early study results
EANM Congress – Early study results Early results presented at European Association of Nuclear Medicine on 21-Oct-17 For personal use only Clinical Performance • Excellent local disease control – Disease Control Rate (DCR) 100% @ Week 8 • Early and substantial tumour volume reductions – up to 73% vo
Slide 8: Delivering a single dose of OncoSil microparticles
Delivering a single dose of OncoSil™ microparticles For personal use only A single dose is implanted into the body of the tumour Delivers 100 Gy of radiation to the tumour mass Gholami 2017. Int J Rad Oncol Biol Phys. 99; 4: 1029-1038 OncoSil Medical 8
Slide 9: Implantation via Ultrasound guided endoscopy
Implantation via Ultrasound guided endoscopy EUS For personal use only OncoSil™ device delivery via EUS is considered easy to use for implantation (zoomed in) Tumour Outline Needle positioning OncoSil™ deposition OncoSil Medical 9
Slide 10: Images post implantation
Images post implantation For personal use only Coronal Sagittal Transverse Day 1 Scan Day 7 Scan OncoSil Medical 10
Slide 11: Target markets
UK (Launch market) 1 Pancreatic cancer 8,747 Liver cancer 4,186 European Union1 For personal use only Pancreatic cancer 79,331 Liver cancer 51,785 Target markets Annual incidence China1 Global opportunity2 United States1 Pancreatic cancer 65,727 Liver cancer 351,000 Pancreatic cancer 42,885 Pancreat
Slide 12: OncoSil's commercial path has precedent
OncoSil’s commercial path has precedent SirTex provides a useful case study to demonstrate the potential commercial journey For personal use only for OncoSil due to similarities in addressable market 24-Aug-00 24-May-02 Listed on the ASX with Phase II First patient treated in the USA Ramp up in SIR
Slide 13: Highly credentialed Board of Directors
Highly credentialed Board of Directors For personal use only • Board and management are experienced leaders in the pharmaceutical and medical device space, having held senior positions at Cochlear (ASX:COH), Sirtex Medical (ASX:SRX), ABIVAX, Baxter International, Roche and more • Extensive leadershi
Slide 14: Deeply experienced management team
Deeply experienced management team Revamped leadership team For personal use only • Management team experienced leaders in the medical device space having held senior positions at Sirtex Medical (ASX:SRX) • Extensive leadership experience in clinical studies, commercialisation and manufacturing & op
Slide 15: Daniel Kenny, CEO & Managing Director
For personal use only Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au OncoSil Medical Ltd www.oncosil.com.au T: +61 2 9223 3344 F: +61 2 9252 3988 OncoSil Medical 15